Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
China
Pharma
BIO-WuXi, Takeda, FDA-Carvykti—Fierce Pharma Asia
WuXi AppTec left BIO amid alleged biosecurity concerns. Takeda will close a gene therapy plant. The FDA flagged early deaths in a Carvykti trial.
Angus Liu
Mar 15, 2024 10:15am
Eisai, Sumitomo, Kyowa Kirin and more—Fierce Pharma Asia
Mar 8, 2024 9:42am
AstraZeneca finally drops roxadustat US rights
Feb 27, 2024 11:28am
BeiGene added 1,400 employees as key cancer drugs expand
Feb 26, 2024 11:03am
FDA slams Chinese API maker Sichuan Deebio with warning letter
Feb 22, 2024 9:10am
Takeda, WuXi, LianBio—Fierce Pharma Asia
Feb 16, 2024 8:24am